Lykos Therapeutics

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

Advocates for psychedelics have cast a concerned glance at the news that the leader in the field, Compass Pathways, has again pushed back pivotal data readouts for its treatment-resistant depression (

Lykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress

Bionomics Limited has been all-in on its allosteric ion channel modulator BNC210 in neuropsychiatric indications for years and is bullish about moving forward now that the drug met the primary endpoi